Douglas Lane & Associates LLC raised its stake in shares of Stryker Co. (NYSE:SYK) by 5.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,831 shares of the medical technology company’s stock after acquiring an additional 100 shares during the period. Douglas Lane & Associates LLC’s holdings in Stryker were worth $287,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital International Investors purchased a new stake in shares of Stryker during the 3rd quarter valued at about $831,822,000. Capital World Investors increased its holdings in Stryker by 987.2% in the 3rd quarter. Capital World Investors now owns 1,657,979 shares of the medical technology company’s stock worth $294,590,000 after acquiring an additional 1,505,479 shares in the last quarter. Winslow Capital Management LLC increased its holdings in Stryker by 215,255.1% in the 3rd quarter. Winslow Capital Management LLC now owns 1,109,079 shares of the medical technology company’s stock worth $197,061,000 after acquiring an additional 1,108,564 shares in the last quarter. FMR LLC increased its holdings in Stryker by 24.0% in the 2nd quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock worth $899,662,000 after acquiring an additional 1,032,333 shares in the last quarter. Finally, Alliancebernstein L.P. increased its holdings in Stryker by 61.1% in the 3rd quarter. Alliancebernstein L.P. now owns 2,448,502 shares of the medical technology company’s stock worth $435,050,000 after acquiring an additional 928,279 shares in the last quarter. Institutional investors and hedge funds own 73.38% of the company’s stock.
In other news, VP Bijoy Sagar sold 2,361 shares of Stryker stock in a transaction on Friday, December 7th. The stock was sold at an average price of $171.24, for a total transaction of $404,297.64. Following the completion of the sale, the vice president now directly owns 2,361 shares in the company, valued at $404,297.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Michael Damon Hutchinson sold 15,995 shares of Stryker stock in a transaction on Friday, February 8th. The stock was sold at an average price of $180.49, for a total value of $2,886,937.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,259 shares of company stock valued at $7,515,747. 7.30% of the stock is owned by corporate insiders.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a report on Monday, February 4th. Cantor Fitzgerald reissued a “neutral” rating on shares of Stryker in a report on Friday, January 18th. Oppenheimer set a $170.00 price objective on shares of Stryker and gave the company a “hold” rating in a report on Friday, November 9th. SunTrust Banks increased their price objective on shares of Stryker to $205.00 and gave the company a “positive” rating in a report on Monday, February 4th. Finally, Canaccord Genuity increased their price objective on shares of Stryker from $185.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, January 30th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $185.37.
Shares of NYSE SYK traded up $1.91 during midday trading on Friday, reaching $182.66. 1,317,710 shares of the stock traded hands, compared to its average volume of 1,697,556. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.21 and a current ratio of 2.02. The company has a market capitalization of $67.63 billion, a P/E ratio of 24.99, a P/E/G ratio of 2.22 and a beta of 0.86. Stryker Co. has a one year low of $144.75 and a one year high of $182.69.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.03. The company had revenue of $3.80 billion during the quarter, compared to the consensus estimate of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. As a group, equities analysts predict that Stryker Co. will post 8.12 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.52 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a yield of 1.14%. Stryker’s dividend payout ratio is presently 28.45%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?